The 'Never-Met' Resistance of Urinary Tract Pathogens to Novel Antibiotics
Abstract
Background: Antimicrobial resistance (AMR) is rapidly escalating among urinary tract pathogens, posing a pressing challenge for human and veterinary medicine. Urinary tract infections (UTIs), a common disease in humans and domestic animals like dogs and cats, are primarily caused by Gram-negative bacteria such as Escherichia coli, Klebsiella spp., Proteus spp., and Enterobacter spp. These pathogens are notorious for their ability to develop resistance against commonly used antimicrobials. Traditional antibiotics, particularly beta-lactams and fluoroquinolones, are losing their effectiveness due to the rising resistance levels. This alarming trend necessitates exploring novel antibacterial agents to manage and treat multidrug-resistant (MDR) pathogens. This study aims to compare the efficacy of the novel antibacterial agents cefiderocol, ceftolozane/tazobactam, eravacycline, lefamulin, and omadacycline with traditional antibiotics against MDR urinary tract pathogens from humans, dogs, and cats. Understanding the effectiveness of these new agents is crucial for developing better strategies to manage UTIs and combat AMR. Materials, Methods & Results: This study collected and analyzed urinary tract pathogens from humans, dogs, and cats between 2021 and 2023. The bacterial isolates, including E. coli, Klebsiella pneumoniae, Proteus spp., and Enterobacter spp., were identified using the Vitek system. The isolates showed resistance to at least 3 different classes of antibiotics,…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.